| 1 |
Contreras G,Pardo V,Leelereq B,et al. Sequential therapies for proliferative lupus nephritis [J]. New Engl J Med, 2004, 350(10):971-980.
|
| 2 |
Okada Y1, Nakamura K, Kodama T, et al. Thiopurine methyltransferase genotype and phenotype status in Japanese patients with systemic lupus erythematosus [J]. Biol Pharm Bull,2005, 28(11):2117-2119.
|
| 3 |
Zhu Q, Cao Q. Thiopurine methyltransferase gene polymorphisms and activity in Chinese patients with inflammatory bowel disease treated with azathioprine [J]. Chin Med J (Engl), 2012, 125(20):3665-3670.
|
| 4 |
Chisick L, Oleschuk C, Bernstein CN. The utility of thiopurine methyltransferase enzyme testing in inflammatory bowel disease [J].Can J Gastroenterol,2013,27(1):39-43.
|
| 5 |
Naughton MA, Battaglia E, O'Brien S, et al. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine [J]. Rheumatology,1999,38(7):640-644.
|
| 6 |
Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: molecular mechanisms and clinical importance[J]. Pharmacology,2000,61(3):136-146.
|
| 7 |
Weinshilboum R. Thiopurine Pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase [J]. Drug Metab Dispos,2001,29(4 Pt 2):601-605.
|
| 8 |
Lee EJ, Kalow W. Thiopurine S-methyltransferase activity in a Chinese population [J]. Clin Pharmacol Ther, 1993, 54(1): 28-33.
|
| 9 |
Relling MV, Gardner EE, Sandborn WJ, et al. Clinical Pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing [J].Clin Pharmacol Ther,2011,89(3):387-391.
|
| 10 |
Kham SK1, Soh CK, Aw DC, et al. TPMT*26 (208F- ＞L), a novel mutation detected in a Chinese [J]. Br J Clin Pharmacol,2009,68(1):120-123.
|